4/14
06:04 am
ntla
2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]
Low
Report
2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]
4/6
09:16 am
ntla
Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]
Low
Report
Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]
3/25
01:40 pm
ntla
Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]
Low
Report
Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]
3/19
03:09 pm
ntla
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]
Low
Report
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]
3/18
07:42 am
ntla
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]
Medium
Report
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]
3/18
07:30 am
ntla
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Medium
Report
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
3/9
09:53 am
ntla
Is Intellia Therapeutics Stock a Buy Now? [Yahoo! Finance]
Low
Report
Is Intellia Therapeutics Stock a Buy Now? [Yahoo! Finance]
3/6
10:45 am
ntla
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]
Low
Report
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]
2/29
12:50 pm
ntla
Intellia Therapeutics Is On The Move [Seeking Alpha]
Low
Report
Intellia Therapeutics Is On The Move [Seeking Alpha]
2/29
06:06 am
ntla
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now [Yahoo! Finance]
Low
Report
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now [Yahoo! Finance]
2/28
11:25 am
ntla
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
Neutral
Report
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
2/27
11:22 am
ntla
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average [Yahoo! Finance]
Medium
Report
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average [Yahoo! Finance]
2/25
08:19 am
ntla
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
Medium
Report
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
2/24
07:27 am
ntla
Intellia Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
Medium
Report
Intellia Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
2/23
01:07 pm
ntla
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update [Yahoo! Finance]
Low
Report
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update [Yahoo! Finance]
2/23
12:34 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/23
12:08 pm
ntla
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? [Yahoo! Finance]
2/23
10:12 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $72.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $72.00 to $73.00. They now have a "buy" rating on the stock.
2/23
09:36 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $32.00 price target on the stock, down previously from $136.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $32.00 price target on the stock, down previously from $136.00.
2/22
08:23 am
ntla
Intellia Therapeutics Inc (NTLA) Reports Full-Year 2023 Financial Results and Operational Progress [Yahoo! Finance]
Low
Report
Intellia Therapeutics Inc (NTLA) Reports Full-Year 2023 Financial Results and Operational Progress [Yahoo! Finance]
2/22
07:44 am
ntla
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]
Low
Report
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]
2/22
07:30 am
ntla
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
Low
Report
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
2/17
02:13 am
ntla
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? [Yahoo! Finance]
Low
Report
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? [Yahoo! Finance]
2/15
06:08 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
2/15
07:52 am
ntla
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates [Yahoo! Finance]
Low
Report
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates [Yahoo! Finance]